Tonix Pharmaceuticals Announces AI Collaboration with X-Chem to Develop Broad-Spectrum AntiviralsGlobeNewsWire • Tuesday
The Rush for Non-Addictive Painkillers to Counter the Opioid Crisis Puts Two Companies Close to FDA DecisionsAccesswire • 10/01/24
Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering the Subcutaneous Delivery of FDA-Approved Zembrace® SymTouch® to Treat MigrainesGlobeNewsWire • 09/27/24
Tonix Pharmaceuticals Announces Issuance of U.S. Patent by the United States Patent and Trademark Office Covering the Intranasal Delivery of FDA-Approved Tosymra® to Treat MigrainesGlobeNewsWire • 09/19/24
New Hope for Mpox? How TNX-801 Could Meet the WHO's Vaccine Targets for a Safer, Single-Dose SolutionAccesswire • 09/18/24
Tonix Pharmaceuticals Announces That its Single Dose Mpox Vaccine Candidate TNX-801 Aligns with WHO's Newly Issued Preferred Target Product Profile for Mpox Vaccines in Global Health EmergencyGlobeNewsWire • 09/16/24
Tonix Pharmaceuticals Launches National Awareness Campaign on the Impact of Gastroparesis or Stomach Paralysis on the Absorption of Oral Migraine Medications at PAINWeekGlobeNewsWire • 09/06/24
As Research into Pain Accelerates, a Newly Recognized Type of Pain Comes to the Forefront - Tonix Targets it with FDA-Fast Track-Designated TNX-102 SLAccesswire • 09/04/24
Tonix Pharmaceuticals Presented Data from Two Posters on TNX-102 SL for Reduction of Acute Stress Reaction and Prevention of PTSD and One Poster for Wound Healing at the 2024 Military Health System Research Symposium (MHSRS)GlobeNewsWire • 08/29/24
Tonix Pharma Collaborates With World's Largest Vaccine Manufacturer For Mpox VaccineBenzinga • 08/26/24
Tonix Pharmaceuticals and Bilthoven Biologicals to Collaborate on Advancing Development of Tonix's Mpox Vaccine, TNX-801GlobeNewsWire • 08/26/24
Modern Twist to Centuries-Old Smallpox Vaccine Poised to Combat Deadly Mpox Strain as WHO Declares Global EmergencyAccesswire • 08/23/24
Tonix Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational HighlightsGlobeNewsWire • 08/19/24
Tonix Pharmaceuticals Provides Update on the Development of Its Single Dose Live Attenuated Virus Vaccine Candidate for Mpox, TNX-801, as WHO Declares Mpox Outbreak a Global Health EmergencyGlobeNewsWire • 08/16/24
FDA Recognizes Fibromyalgia as a 'Serious Condition' And Fast-Tracks New Drug CandidateAccesswire • 08/01/24
Tonix Pharmaceuticals Announces Potential Positive Impact of the U.S. National Academies (NASEM) New Definition of Long COVID on the Size of the Fibromyalgia Market for Tonmya™GlobeNewsWire • 07/31/24
Tonix Pharmaceuticals Granted Fast Track Designation by FDA for Tonmya™ for FibromyalgiaGlobeNewsWire • 07/25/24
Beyond "One Bug, One Drug" - Tonix Pharmaceuticals Secures Up To $34 Million In Funding From The U.S. Department Of Defense To Develop a Broad-Spectrum AntiviralAccesswire • 07/24/24
Tonix Pharmaceuticals, Set to File an NDA for Tonmya for the Management of Fibromyalgia, is Planning Expected Launch in 2H 2025Accesswire • 07/17/24
Tonix Pharmaceuticals Announces Pricing of Approximately $4.0 Million Public OfferingGlobeNewsWire • 07/09/24
Tonix Pharmaceuticals Reports Final Positive Pre-NDA Meeting with FDA for Tonmya™ for the Management of FibromyalgiaGlobeNewsWire • 07/08/24
Tonix Pharmaceuticals Awarded Up to $34 Million U.S. Department of Defense Contract for Accelerated Development of Broad-Spectrum Antiviral ProgramGlobeNewsWire • 07/01/24
